Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Car-t cell therapy
What CAR-T cell therapy is, how T-cells are collected, re-engineered and reinfused to fight blood cancers, what clinical evidence shows about remission rates, how it compares with chemotherapy and stem cell transplants, approximate costs in Turkey against the UK, US and Germany, hospital stay timelines, cytokine release syndrome and other risks, and how to verify accredited haematology centres.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for CAR-T Cell Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is car-t cell therapy and how does it work?
Car-t cell therapy (chimeric antigen receptor T-cell therapy) is an advanced form of cellular immunotherapy that genetically reprograms a patient's own immune cells to target and eliminate haematological cancers. Normal T-lymphocytes defend the body against pathogens and abnormal cells, but malignant cells often evade detection by downregulating surface antigens or releasing immunosuppressive signals. In CAR-T therapy, a patient's T-cells are harvested via apheresis, genetically modified in an accredited cleanroom laboratory to express synthetic receptors targeted to cancer antigens (such as CD19 or BCMA), and reinfused into the bloodstream. These reprogrammed cells multiply, locate the targeted malignant cells, and destroy them.
Unlike standard pharmaceuticals, CAR-T is an autologous "living drug" manufactured individually for each patient. It is used primarily for relapsed or refractory blood cancers within oncology treatments in Turkey and international specialised cancer centres. This guide explains how the cellular treatment works, what clinical trials show, approximate costs in Turkey compared with the UK, US and Germany, hospital stay timelines, potential complications, and how to verify accredited haematology facilities.
How are CAR T-cells manufactured and infused?
The car-t cell therapy process follows five coordinated clinical and laboratory stages:
- T-cell collection (leukapheresis): The patient is connected to a blood-filtering apheresis machine that separates and collects white blood cells over three to five hours while returning red cells and plasma to the circulation.
- Cellular reprogramming: In an accredited cleanroom, a disarmed viral vector inserts the synthetic chimeric receptor gene into the T-cells, enabling them to recognise specific tumour markers. The modified cells are cultured and expanded over two to three weeks until hundreds of millions of cells are ready.
- Bridging therapy: While cells are being cultured, patients with high tumour burdens may receive short courses of targeted therapy or low-dose systemic treatments to stabilise disease progression.
- Lymphodepleting conditioning: Two to five days before infusion, the patient receives conditioning chemotherapy (typically fludarabine and cyclophosphamide) to deplete native white blood cells, creating space and growth factors for the incoming cells.
- Intravenous infusion: The thawed CAR-T cell product is infused through a central or peripheral vein in a specialised inpatient room over fifteen to thirty minutes.
Does car-t cell therapy actually work? What the clinical evidence says
Published clinical trials and international patient registries confirm that car-t cell therapy can induce profound remissions in patients with aggressive blood cancers who have exhausted standard treatment lines. Health authorities including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the therapy after pivotal trials showed complete remission rates between 60% and 80% in relapsed paediatric and young adult B-cell acute lymphoblastic leukaemia (ALL), and overall response rates between 50% and 75% in relapsed diffuse large B-cell lymphoma (DLBCL). In relapsed multiple myeloma, BCMA-directed therapies produce overall response rates exceeding 70% in heavily pretreated patient groups.
Despite these high response rates, CAR-T is not a universal cure. A significant proportion of patients experience disease recurrence after several months or years due to antigen escape (where cancer cells lose the surface protein) or because the engineered cells cease to persist in the bloodstream. Furthermore, CAR-T has not yet demonstrated reliable efficacy in solid tumours such as breast, bowel, or lung cancer, where the physical tumour microenvironment prevents immune cell penetration. An ethical medical team will provide clear, individualised evidence rather than guaranteeing permanent cure.
CAR-T cell therapy cost in Turkey compared with the UK, US and Germany
The figures below indicate approximate total medical cost ranges per treatment course, covering cell collection, manufacturing, conditioning, inpatient hospitalisation, and acute post-infusion monitoring. They are broad comparative estimates rather than individual hospital quotes.
| Country | Approximate cost range |
|---|---|
| Turkey | €65,000 – €180,000 |
| United Kingdom | €320,000 – €500,000 |
| United States | €450,000 – €950,000 |
| Germany | €280,000 – €480,000 |
The total car-t cell therapy price depends heavily on whether the hospital uses a commercially licensed pharmaceutical product or an academic cellular product prepared in certified university hospital cleanrooms. Additional price factors include the duration of inpatient hospitalisation, the necessity of intensive care support for severe immune reactions, and the need for biological rescue medicines such as tocilizumab. A transparent medical quote must detail cell manufacturing, inpatient bed days, haematologist fees, and emergency medication provisions in writing.
CAR-T cell therapy vs stem cell transplant and targeted therapy
Patients with advanced haematological conditions often evaluate CAR-T alongside other high-level oncology options. Each approach serves a different therapeutic role based on disease burden, previous treatments, and individual patient fitness.
| Treatment approach | Best suited to | Typical limits |
|---|---|---|
| CAR-T cell therapy | Relapsed or refractory B-cell leukaemias, non-Hodgkin lymphomas, and multiple myeloma after two or more prior lines of therapy have failed. | Requires a 2–3 week manufacturing period; risk of acute inflammatory toxicities; high overall cost; limited utility in solid tumours. |
| Allogeneic stem cell transplant (HSCT) | High-risk leukaemias with an available matching donor, replacing diseased marrow to establish a donor-versus-tumour immune graft. | Requires compatible HLA donor; carries risk of severe graft-versus-host disease (GvHD); involves prolonged immunosuppression. |
| Targeted therapy & chemotherapy | Frontline induction, disease debulking, or bridging regimens designed to rapidly lower tumour burden prior to cellular infusion. | Cancer cells frequently develop secondary drug resistance; broad systemic side effects; declining response rates in later treatment lines. |
Unlike allogeneic stem cell transplantation, autologous CAR-T uses the patient's own modified cells, completely avoiding graft-versus-host disease. Depending on clinical circumstances, CAR-T can serve either as a standalone consolidative therapy or as a bridge to achieve deep remission before a donor transplant.
Who is an eligible candidate for CAR-T cell therapy, and who is not?
Eligibility for cellular immunotherapy requires thorough multidisciplinary evaluation by specialised haematologists and oncology review boards.
Good candidates typically present with:
- Confirmed relapsed or refractory B-cell lymphoma, B-cell ALL, or multiple myeloma after failing at least two prior lines of systemic therapy.
- Adequate general functional health (typically ECOG performance status 0 to 1), indicating the physical resilience needed to tolerate temporary systemic immune activation.
- Preserved major organ function, including acceptable cardiac ejection fraction, adequate lung capacity, and stable renal and liver parameters.
- Controlled disease kinetics allowing a two- to three-week window for cell manufacturing and laboratory testing.
Poor candidates or contraindications include:
- Active, severe systemic bacterial, viral, or fungal infections that must be cleared before conditioning chemotherapy.
- Severe irreversible organ failure involving the kidneys, lungs, or cardiovascular system.
- Rapidly progressing central nervous system disease that precludes waiting for cell processing.
- Pregnancy or breastfeeding, due to the severe toxicity of conditioning chemotherapy.
What to expect from treatment outcomes: remission, scans and realistic results
Assessing treatment results following CAR-T infusion requires objective clinical testing rather than early symptom relief. During the first four weeks, engineered T-cells expand rapidly in the body, which can produce temporary swelling in tumour areas or lymph nodes known as pseudo-progression.
Formal clinical response is typically measured around day 28 to day 30 post-infusion, followed by repeat checks at three, six, and twelve months. For lymphomas, response is evaluated with PET-CT scans measuring metabolic tumour activity. For leukaemias and myeloma, doctors assess bone marrow biopsies and flow cytometry for measurable residual disease (MRD). Achieving MRD negativity—meaning no malignant cells can be detected at a sensitivity of one in 100,000 cells—is strongly associated with durable remissions. However, clear scans at one month do not eliminate the risk of late recurrence, making regular haematological monitoring essential.
Treatment timeline, hospital stay and recovery milestones
Undergoing CAR-T cell therapy in Turkey typically requires an overall stay of four to six weeks, structured into clearly defined medical stages:
- Week 1 (Evaluation & leukapheresis): Inpatient or outpatient assessment, including infectious disease screening, organ evaluations, and blood collection to harvest T-cells.
- Weeks 2–3 (Cell manufacturing & bridging): The laboratory cultures and reprograms the cells. Patients remain under medical observation and may receive bridging treatment if needed.
- Days -5 to Day 0 (Conditioning & infusion): Inpatient admission for three days of lymphodepleting chemotherapy, followed by two days of rest and the intravenous infusion of the CAR-T cells.
- Days 1–14 (Acute inpatient monitoring): The patient stays in a specialised hospital room with frequent monitoring for body temperature, blood pressure, neurological function, and daily blood counts.
- Days 15–30 (Subacute outpatient care): After discharge from the ward, patients stay in accommodation close to the hospital for twice-weekly check-ups and day-28 restaging scans before clearance to fly.
During the car-t cell therapy recovery phase after returning home, the immune system takes three to twelve months to rebuild. White blood cell counts and normal antibody levels remain low, requiring prophylactic medications and periodic antibody replacement injections coordinated with your local haematologist.
Risks, side effects and safety considerations
Because CAR-T therapy triggers an intense immune response against cancer cells, it carries specific, well-characterised risks documented by regulatory bodies such as the FDA and the European Society for Blood and Marrow Transplantation (EBMT):
- Cytokine Release Syndrome (CRS): Rapid T-cell activation releases large amounts of inflammatory cytokines. Symptoms range from mild fever and body aches to severe low blood pressure, breathing difficulties, and capillary leakage. Medical teams treat CRS promptly using the targeted antidote tocilizumab and intravenous steroids.
- Immune effector cell-associated neurotoxicity syndrome (ICANS): In some patients, inflammatory mediators cross into the central nervous system, causing confusion, speech hesitation, handwriting impairment, or drowsiness. Dedicated hospital staff conduct regular neurological scoring to detect and treat these symptoms with corticosteroids.
- Prolonged cytopenias: Reduced red blood cells, white blood cells, and platelets often persist for several weeks after conditioning chemotherapy, occasionally requiring temporary transfusions or growth-factor injections.
- B-cell aplasia and infection risk: Because CD19-directed CAR-T cells also target healthy B-cells, antibody production remains depressed for months, increasing susceptibility to infections and requiring regular immunoglobulin replacement therapy.
How to choose a specialised haematology centre and red flags
Cellular therapies should only be carried out in accredited hospitals equipped with comprehensive haematology infrastructure. Look for centres holding recognised accreditations such as JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) or certified GMP cleanrooms.
Key markers of a reliable centre include:
- A dedicated haematology and stem cell unit led by certified specialists with direct experience managing cellular therapies.
- An on-site intensive care unit with doctors trained in treating cytokine release syndrome and acute neurotoxicity.
- Immediate, guaranteed stock of rescue medications, including tocilizumab.
- A structured post-treatment discharge plan that coordinates clinical handovers and blood monitoring with your home medical team.
Red flags include clinics that promise guaranteed remissions, clinics quoting a price without examining complete biopsy and flow cytometry reports, or facilities without specialised isolation rooms. Review how our process works to understand our hospital standards, or request a detailed review through our free quote service.
Key questions to ask your medical oncology team
Before proceeding with cellular immunotherapy, discuss these critical points with the treating haematologist:
- Which specific CAR-T cell construct do you recommend for my diagnosis, and is it a commercial or academic product?
- How many cellular therapy procedures has your medical team performed, and what is your protocol for managing severe CRS?
- What conditioning chemotherapy will I receive, and will I need bridging therapy while my cells are being prepared?
- Are intensive care monitoring and rescue drugs like tocilizumab included in the quotation?
- What tests are performed at day 28 before I am cleared to fly home?
- How will your team communicate with my domestic haematologist to supervise my ongoing blood counts and antibody levels?
Hospitals with Oncology in Turkey
Frequently asked questions
CAR-T cell therapy is an advanced immunotherapy that genetically modifies a patient's own T-cells to recognise and destroy specific cancer cells. It is primarily used for relapsed or refractory blood cancers, including acute lymphoblastic leukaemia, aggressive non-Hodgkin lymphomas, and multiple myeloma, after standard treatments have proved unsuccessful.
Currently, CAR-T cell therapy is mainly effective against haematological cancers of the blood and bone marrow. Its application in solid tumours such as breast, colon, or lung cancer remains largely experimental in clinical trials, because dense tumour microenvironments and variable surface targets make cellular penetration much more challenging.
CAR-T cell therapy in Turkey typically ranges from €65,000 to €180,000, depending on whether an academic cleanroom or commercial product is used, the required hospitalisation length, and supportive medications. In comparison, total treatment in the UK, Germany, or the US frequently exceeds €300,000 to €800,000.
Pivotal clinical studies report complete remission rates between 60% and 80% for relapsed B-cell acute lymphoblastic leukaemia, and overall response rates of 50% to 75% in aggressive lymphomas. However, some patients experience subsequent relapse, so long-term remissions vary according to disease type and prior therapies.
CAR-T therapy modifies your own immune cells to target cancer cells without requiring a matched donor or causing graft-versus-host disease. Allogeneic stem cell transplantation replaces the entire bone marrow using donor cells. CAR-T is often used when transplants fail or as a bridging step before transplantation.
Patients generally spend four to six weeks in Turkey. This includes initial cell harvesting, a two- to three-week laboratory preparation window, conditioning chemotherapy, cell infusion, and approximately two weeks of close inpatient observation for immune reactions, followed by day-28 restaging tests before travel clearance.
The two most significant risks are cytokine release syndrome, causing high fever, low blood pressure, and inflammation, and immune effector cell-associated neurotoxicity syndrome, causing confusion or speech difficulty. Both conditions are treatable with drugs like tocilizumab and steroids in specialised inpatient haematology units.
Repeating CAR-T therapy is complex. If cancer relapses because the original target antigen is lost, re-administering the same product is ineffective. If the target antigen persists, a second infusion or a different construct targeting another antigen may be considered, but response rates are generally lower than the initial treatment.
Eligible patients typically have relapsed or refractory B-cell haematological malignancies that have progressed after two or more prior lines of therapy. Candidates must have adequate heart, kidney, and lung function and an acceptable performance status to tolerate temporary systemic immune responses during cell expansion.
The intravenous infusion itself is painless and resembles a routine blood transfusion taking fifteen to thirty minutes. However, the subsequent immune activation over the following one to two weeks frequently causes flu-like symptoms, high fevers, fatigue, and muscle aches that require careful supportive hospital care.
Patient stories